Drug Safety

, Volume 20, Issue 4, pp 361–375 | Cite as

Treating Allergic Rhinitis in Pregnancy

Safety Considerations
  • Paolo Mazzotta
  • Ronen Loebstein
  • Gideon Koren
Practical Drug Safety

Abstract

Allergic rhinitis affects approximately one-third of women of childbearing age. As a result, symptoms ranging from sneezing and itching to severe nasal obstruction may require pharmacotherapy. However, product labels state that medications for allergic rhinitis should be avoided during pregnancy due to lack of fetal safety data, even though the majority of the agents have human data which refute these notions. We present a systematic and critical review of the medical literature on the use of pharmacotherapy for the management of allergic rhinitis during pregnancy. Electronic databases and other literature sources were searched to identify observational controlled studies focusing on the rate of fetal malformations in pregnant women exposed to agents used to treat allergic rhinitis and related diseases compared with controls.

Immunotherapy and intranasal sodium cromoglycate (Cromolyn) and beclomethasone would be considered as first-line therapy, both because of their lack of association with congenital abnormalities and their superior efficacy to other agents. First-generation (e.g. chlorpheniramine) and second-generation (e.g. cetirizine) antihistamines have not been incriminated as human teratogens. However, first-generation antihistamines are favoured over their second generation counterparts based on their longevity, leading to more conclusive evidence of safety. There are no controlled trials with loratadine and fexofenadine in human pregnancy.

Oral, intranasal and ophthalmic decongestants (e.g. pseudoephedrine, phenylephrine and oxymetazoline, respectively) should be considered as second-line therapy, although further studies are needed to clarify their fetal safety. No human reproductive studies have been reported with the ophthalmic antihistamines ketorolac and levocabastine, although preliminary data reported suggest no association between pheniramine and congenital malformations. There are no documented epidemiological studies with intranasal corticosteroids (e.g. budesonide, fluticasone propionate, mometasone) during pregnancy; however, inhaled corticosteroids (e.g. beclomethasone) have not been incriminated as teratogens and are commonly used by pregnant women who have asthma.

In summary, women with allergic rhinitis during pregnancy can be treated with a number of pharmacological agents without concern of untoward effects on their unborn child. Although the choice of agents in part should be based on evidence of fetal safety, issue of efficacy needs to be addressed in order to optimally manage this condition.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mabry RL. Intranasal steroid injection during pregnancy. South Med J 1980; 73(9): 1176–9PubMedCrossRefGoogle Scholar
  2. 2.
    Mabry RL. Rhinitis of pregnancy. South Med J 1986; 79: 965–71PubMedCrossRefGoogle Scholar
  3. 3.
    Beeley L. Adverse effects of drugs in later pregnancy. Clin Obstet Gynecol 1981; 8: 275–90Google Scholar
  4. 4.
    Sorri M, Bortikanen-Sorri AL, Karja J. Rhinitis during pregnancy. Rhinology 1980; 18: 83–6PubMedGoogle Scholar
  5. 5.
    Schatz M, Zeiger RS. Diagnosis and management of rhinitis during pregnancy. Allergy Proc 1988; 9: 545–54PubMedCrossRefGoogle Scholar
  6. 6.
    Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977Google Scholar
  7. 7.
    United States Food and Drug Administration labelling and prescription drug advertising: content and format for labelling for human prescription drugs. Fed Regist 1979; 44 (124): 37434-67Google Scholar
  8. 8.
    Teratology Society Public Affairs Committee. FDA classification of drugs for teratogenic risk. Teratology 1994; 49: 446–7CrossRefGoogle Scholar
  9. 9.
    Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 5th ed. Baltimore (MD): Williams and Wilkins, 1998Google Scholar
  10. 10.
    Schardein JL. Chemically induced birth defects. New York: Marcel Dekker Inc., 1993Google Scholar
  11. 11.
    Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65(4): 451–5PubMedGoogle Scholar
  12. 12.
    Seto A, Einarson T, Koren G. Evaluation of brompheniramine safety in pregnancy. Reprod Toxicol 1993; 7(4): 393–5PubMedCrossRefGoogle Scholar
  13. 13.
    Physicians’ Desk Reference. New Jersey: Medical Economics Company, 1989Google Scholar
  14. 14.
    Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA 1981; 246(4): 343–6PubMedCrossRefGoogle Scholar
  15. 15.
    Scialli AR, Lione A. Pregnancy effects of specific medications used to treat asthma and immunological diseases. In: Schatz M, Zeiger RS, Claman HN, editors. Asthma and immunological diseases in pregnancy and early infancy. New York: Marcel Dekker Inc., 1998Google Scholar
  16. 16.
    Saxen I. Cleft palate and maternal diphenhydramine intake. Lancet 1974; I: 407–8CrossRefGoogle Scholar
  17. 17.
    Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971; 1: 523–7PubMedCrossRefGoogle Scholar
  18. 18.
    Kullander S, Kallen B. A prospective study of drugs and pregnancy. II. Anti-emetic drugs. Acta Obstet Gynecol Scand 1976; 55: 105–11PubMedCrossRefGoogle Scholar
  19. 19.
    Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1976; 15: 57–64CrossRefGoogle Scholar
  20. 20.
    Greenberg G, Inman WHW, Weatherall JAC, et al. Maternal drug histories and congenital abnormalities. BMJ 1977; 2: 853–6PubMedCrossRefGoogle Scholar
  21. 21.
    Mitchell AA, Schwingl PJ, Rosenberg L, et al. Birth defects in relation to Bendectin use in pregnancy: II: pyloric stenosis. Am J Obstet Gynecol 1983; 147(7): 737–42PubMedGoogle Scholar
  22. 22.
    Shepard TH. Catalog of teratogenic agents. Baltimore (MD): The John Hopkins University Press, 1992Google Scholar
  23. 23.
    Erez S, Schifrin BS, Dirim O. Double-blind evaluation of hydroxyzine as an antiemetic in pregnancy. J Reprod Med 1971; 7: 57–9Google Scholar
  24. 24.
    Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78: 183–6PubMedCrossRefGoogle Scholar
  25. 25.
    Kamijima M, Sakai, Kinoshita K, et al. Reproductive and developmental toxicity studies of cetirizine in rats and rabbits. Clin Report 1994; 28: 1877–903Google Scholar
  26. 26.
    Pastuszak A, Schick B, D’Alimonte D, et al. The safety of astemizole in pregnancy. J Allergy Clin Immunol 1996; 98: 748–50PubMedCrossRefGoogle Scholar
  27. 27.
    Schick B, Horn M, Librizzi R, et al. Terfenadine (Scidane) exposure in early pregnancy [abstract]. Teratology 1994; 49(5): 417Google Scholar
  28. 28.
    Aoki Y, Terada Y, Nakamura, et al. Reproductive and developmental toxicity studies of ebastine (2): teratogenicity study in rats. Yakuri to Chiryo 1994; 22: 1193–1215Google Scholar
  29. 29.
    Rothman KJ, Fyler DC, Goldblatt A, et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109(4): 433–9PubMedGoogle Scholar
  30. 30.
    Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985; 313(6): 347–52PubMedCrossRefGoogle Scholar
  31. 31.
    Werler MM, Mitchell AA, Shapiro S. First trimester maternal medications use in relation to gastroschisis. Teratology 1992; 45: 361–7PubMedCrossRefGoogle Scholar
  32. 32.
    Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54: 84–92PubMedCrossRefGoogle Scholar
  33. 33.
    Morrow-Brown H, Storey G. Beclomethasone dipropionate aerosol In long term treatment of perennial and seasonal asthma in children and adults: a report of five and a half years experience in 600 asthmatic patients. Br J Clin Pharmacol 1977; 4: 259S–67SCrossRefGoogle Scholar
  34. 34.
    Greenberger PA, Patterson R. Beclomethasone dipropionate for severe asthma during pregnancy. Ann Intern Med 1983; 98: 478–80PubMedGoogle Scholar
  35. 35.
    Wilson J. Use of sodium cromoglycate during pregnancy. J Pharm Med 1982; 8: 45–51Google Scholar
  36. 36.
    Derbes VJ, Soderman WA. Reciprocal influence of bronchial asthma and pregnancy. Am J Med 1946; 1: 367–75PubMedCrossRefGoogle Scholar
  37. 37.
    Francis N. Abortion aftergrass pollen injection. J Allergy 1941; 12: 559–63CrossRefGoogle Scholar
  38. 38.
    Chester SW Pregnancy and the treatment of hay fever, allergic rhinitis, and pollen asthma. Ann Allergy 1950; 8: 772–3, 798PubMedGoogle Scholar
  39. 39.
    Jensen K. Pregnancy and allergic diseases [letter]. Acta Allergol 1953; 6: 44PubMedGoogle Scholar
  40. 40.
    Maietta AL. The management of the allergic patient during pregnancy. Ann Allergy 1955; 13: 516–22PubMedGoogle Scholar
  41. 41.
    Schaefer G, Silverman F Pregnancy complicated by asthma. Am J Obstet Gynecol 1961; 82: 182PubMedGoogle Scholar
  42. 42.
    Negrini AC, Molinelli G. Alcune observazioni in tempa di terapia iposenzibilizzante in corso di gravidanza [letter]. Folia Allergol (Roma) 1970; 17: 181Google Scholar
  43. 43.
    Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978; 61(4): 268–72PubMedCrossRefGoogle Scholar
  44. 44.
    Shaikh WA. A retrospective study on the safety of immunotherapy in pregnancy. Clin Exp Allergy 1993; 23: 857–60PubMedCrossRefGoogle Scholar
  45. 45.
    Van Allen MI. Fetal vascular disruption: mechanisms and some resulting birth defects. Pediatr Ann 1981; 10: 31–50Google Scholar
  46. 46.
    Hoyme HE, Jones KL, Dixon SD, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics 1990; 85: 743–7PubMedGoogle Scholar
  47. 47.
    Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997; 14(3): 119–24PubMedCrossRefGoogle Scholar
  48. 48.
    Noble SL, Forbes RC, Woodbridge HB. Allergic rhinitis. Am Fam Physician 1995; 51(4): 837–46PubMedGoogle Scholar
  49. 49.
    Edsbacker S, Andersson KE, Ryrfeldt A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharm 1985; 29(4): 477–81CrossRefGoogle Scholar
  50. 50.
    Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476–82PubMedCrossRefGoogle Scholar
  51. 51.
    Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenalaxis activity. J Allergy Clin Immunol 1998; 101(4 Pt 1): 470–4PubMedCrossRefGoogle Scholar
  52. 52.
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomised controlled trials. Am J Respir Crit Care Med 1995; 151: 969–74PubMedGoogle Scholar
  53. 53.
    Field PI, Gillis D. Specific allergen immunotherapy for asthma. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust 1997; 167: 540–44Google Scholar
  54. 54.
    Schatz M, Zeiger RS. Asthma and allergy in pregnancy. Clin Perinatol 1997; 24(2): 407–32PubMedGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Paolo Mazzotta
    • 1
  • Ronen Loebstein
    • 1
  • Gideon Koren
    • 1
  1. 1.Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick ChildrenThe University of TorontoTorontoCanada

Personalised recommendations